Prostate Cancer Clinical Trials in Portland, Oregon

12 studies are recruiting for prostate cancer in Portland, Oregon right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

   Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer ov…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   VA Portland Health Care System ( Site 0038), Portland, Oregon

   Locations

   298 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06925737 on ClinicalTrials.gov

2. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

   The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   Oregon Health & Science University (OHSU), Portland, Oregon

   Locations

   77 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT04585750 on ClinicalTrials.gov

3. Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence

   The impact of fluciclovine (18F) PET on the management of participants with prostate cancer following negative or equivocal PSMA PET Imaging at the time of biochemical recurrence

   Stage

   Phase 4

   Ages

   18 and older

   Site

   Oregon Health & Science University, Portland, Oregon

   Locations

   6 in total

   Run by

   Blue Earth Diagnostics

   See if you can join NCT07569926 on ClinicalTrials.gov

4. MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy

   Doctors leading this study hope to learn about a software that researchers at the University of Chicago have developed to help analyze radiographic images (different techniques for taking images that allow doctors to visualize the body's internal structures) of the prostate. Participation in this r…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Oregon Health & Science University, Portland, Oregon

   Locations

   2 in total

   Run by

   University of Chicago

   See if you can join NCT05710380 on ClinicalTrials.gov

5. A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

   Researchers conducting this study hope to learn about the safety and effectiveness of combining two study drugs, relacorilant and enzalutamide, plus androgen deprivation therapy (ADT), also known as hormone therapy. This study is for individuals who have been diagnosed with advanced, high-risk pros…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Oregon Health & Science University, Portland, Oregon

   Locations

   4 in total

   Run by

   University of Chicago

   See if you can join NCT05726292 on ClinicalTrials.gov

6. A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread

   This study will test a study drug called BPX-601, a CAR-T cell product manufactured from the patient's own T-cells, to see if it can help treat advanced prostate cancer. BPX-601 is a drug that is only used in clinical studies. The study is looking at: * What side effects BPX-601 might cause * What …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Providence Portland Medical Center - Oncology, Portland, Oregon

   Locations

   2 in total

   Run by

   Regeneron Pharmaceuticals

   See if you can join NCT07543055 on ClinicalTrials.gov

7. Precision-Based Genomics in Prostate Cancer

   Background: Prostate cancer is the most common cancer and the second leading cause of death in males in the United States. Researchers want to find additional gene mutations that may increase a man s risk for prostate cancer and may affect how aggressive the disease is. Objective: To look at gene m…

   Stage

   Not phased

   Ages

   18 to 120

   Site

   Oregon Health Sciences University, Portland, Oregon

   Locations

   11 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT04706663 on ClinicalTrials.gov

8. FOG-001 in Locally Advanced or Metastatic Solid Tumors

   The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Oregon Health and Science University, Portland, Oregon

   Locations

   33 in total

   Run by

   Parabilis Medicines, Inc.

   See if you can join NCT05919264 on ClinicalTrials.gov

9. A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

   The purpose of this study is to find out whether tinengotinib in combination with abiraterone acetate and prednisone or enzalutamide is a safe treatment that causes few or mild side effects in people with metastatic castration-resistant prostate cancer (mCRPC).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Oregon Health & Science University, Portland, Oregon

   Locations

   12 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT06457919 on ClinicalTrials.gov

10. International Registry for Men With Advanced Prostate Cancer (IRONMAN)

    Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0/M1 CRPC. The goal is to establish a population-based registry an…

    Stage

    Not phased

    Ages

    21 and older

    Site

    Oregon Health & Science University Hospital, Portland, Oregon

    Locations

    121 in total

    Run by

    Prostate Cancer Clinical Trials Consortium

    See if you can join NCT03151629 on ClinicalTrials.gov

11. cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

    This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gast…

    Stage

    Not phased

    Ages

    40 and older

    Site

    Oregon Health Sciences University, Portland, Oregon

    Locations

    17 in total

    Run by

    Adela, Inc

    See if you can join NCT05366881 on ClinicalTrials.gov

12. Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer

    Pembrolizumab will be administered at a dose of 200 mg will be administered as a 30 minute IV infusion every 3 weeks. Enzalutamide will be administered at dose of 160 mg orally every day. All patients will be required to have at least one high-risk criteria.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    VA Portland Healthcare System, Portland, Oregon

    Run by

    Mark Garzotto, MD

    See if you can join NCT03753243 on ClinicalTrials.gov